强肾片联合龙鹿胶囊治疗多囊卵巢综合征伴胰岛素抵抗患者73例临床观察  

Clinical Observation on Qiangshen Tablets Combined With Longlu Capsules for 73 Cases of Polycystic Ovary Syndrome With Insulin Resistance

作　　者：韦凤[1] 丘彦[1] 何辉玉 

机构地区：[1]重庆医科大学附属第一医院,重庆市袁家岗友谊路1号400016

出　　处：《中医杂志》2014年第16期1386-1389,共4页Journal of Traditional Chinese Medicine

基　　金：重庆市卫生局中医药科技项目资助(2012-2-131)

摘　　要：目的观察强肾片联合龙鹿胶囊治疗多囊卵巢综合征(PCOS)伴胰岛素抵抗(IR)患者的临床疗效。方法将124例PCOS伴IR肾阳虚患者随机分为治疗组73例(给予强肾片及龙鹿胶囊),对照组51例(口服二甲双胍治疗),疗程6个月;两组患者于治疗前后测定内脂素、体重指数(BMI)、空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR),评价排卵恢复率及临床疗效。结果治疗后两组内脂素、BMI、FINS、HOMA-IR水平均较治疗前降低(P<0.01),而FPG治疗前后差异无统计学意义(P>0.05);两组治疗后上述指标比较差异均无统计学意义(P>0.05);治疗组排卵恢复率、临床疗效与对照组比较差异无统计学意义(P>0.05)。结论强肾片联合龙鹿胶囊能有效改善PCOS伴IR患者胰岛素抵抗及排卵情况,且疗效与二甲双胍相当。Objective To observe the efficacy of Qiangshen Tablets combined with Longlu Capsules for polycystic ovary syndrome （PCOS） patients with insulin resistance （IR）. Methods Totally 124 PC OS patients with IR and kidney yang deficiency syndrome were randomized into the treatment group （kidney yang warming and supplementing therapy） of 73 patients and control group （Metformin therapy） of 51 patients. The treatment lasted for 6 months. The visfatin, body mass index （BMI）, fasting plasma glucose （FPG）, fasting insulin （FINS） and homeostasis model as- sessment of insulin resistance （HOMA-IR） were detected before and after treatment, and ovulation recovery rate and clinical efficacy were observed in both groups Results The levels of visfatin, BMI, FINS and HOMA-IR were sig- nificantly decreased in both groups after treatment （ P 〈 0.01 ）. There was no significant difference between before and after treatment in the FPG level in both groups （ P 〉 0. 05 ）. There was no significant difference between groups in above indicators （P 〉 0.05 ）. There was no significant difference between groups in the ovulation recovery rate and clinical efficacy （P 〉 0.05 ）. Conclusion TCM herbs can effectively relieve IR and improve ovulation in PCOS patients, with a same effect as compared with Metformin.

关 键 词：多囊卵巢综合征 内脂素 胰岛素抵抗 肾阳虚 

分 类 号：R711.75[医药卫生—妇产科学]